Monitor cash burn rate and drawdowns on the $50M credit facility; upcoming milestones (orphan drug designations, Phase 1b/2 initiation for TBS-2025) in H2 2026 could provide catalysts. The low cash balance ($1.0M) relative to quarterly burn (~$6.5M) suggests reliance on the credit facility for near-term operations.
Price Chart
Executive Summary
TuHURA Biosciences reported Q2 2026 financial results with cash of $1.0M and operating cash outflow of $13.0M in H1 2026, up from $10.9M in H1 2025. The company highlighted progress on its pipeline (IFx-2.0 Phase 3, TBS-2025 IND filed) and access to a $50M credit facility from its largest shareholder, with $5.7M drawn to date. No revenue or EPS was reported, as the company remains pre-revenue.
Key Facts
- Cash and cash equivalents of $1.0 million at June 30, 2026
- Net cash outflows from operating activities of ($13.0) million for H1 2026 vs ($10.9) million for H1 2025
- Research and development expenses of $6.6 million in Q2 2026 vs $4.9 million in Q2 2025
- General and administrative expenses of $2.1 million in Q2 2026 vs $1.9 million in Q2 2025
- Approximately 63.7 million common shares outstanding at June 30, 2026
- $5.7 million drawn to date on $50 million credit facility from largest shareholder (12% interest, matures 2031)
- ATM program generated $0.3 million in April 2026 and $0.1 million in July 2026
- IND filed for TBS-2025 (VISTA inhibitor) in AML; Phase 1b/2 trial expected to initiate in H2 2026
Financial Impact
No revenue or EPS reported; cash burn increased 19% YoY in H1; cash runway extended into 2028 via credit facility
Risk Factors
- Cash runway dependent on continued draws from credit facility; only $1.0M cash on hand at quarter end
- Clinical trial risks for IFx-2.0 Phase 3 and TBS-2025 Phase 1b/2
- Potential dilution from ATM program and future equity raises
- No revenue stream; operating losses expected to continue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-350425 |
| Document: hura-ex99_1.htm | 0001193125-26-350425 |
| Document: 0001193125-26-350425-index-headers.html | 0001193125-26-350425 |
| Document: 0001193125-26-350425-index.html | 0001193125-26-350425 |
| Document: 0001193125-26-350425.txt | 0001193125-26-350425 |
| 8-K Data (Synthetic) | 0001193125-26-350425 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | 8-K | $1.78 | awaiting T+60 | — | $2.11 (+18.54%) |
Sep 24, 2026 4w ago | 8-K | $2.10 | awaiting T+60 | — | $2.11 (+0.48%) |
Sep 17, 2026 5w ago | 8-K | $2.10 | awaiting T+60 | — | $2.11 (+0.48%) |
Sep 16, 2026 5w ago | 8-K | $2.09 | awaiting T+60 | — | $2.11 (+0.96%) |
Sep 4, 2026 7w ago | 8-K | $2.12 | awaiting T+60 | — | $2.11 (−0.47%) |
Aug 19, 2026 9w ago | 8-K | $2.22 | awaiting T+60 | — | $2.11 (−4.95%) |
Aug 14, 2026 10w ago | 8-K | $2.47 | awaiting T+60 | — | $2.11 (−14.57%) |
Aug 14, 2026 10w ago | Press Release | $2.47 | awaiting T+60 | — | $2.11 (−14.57%) |
Aug 13, 2026 10w ago | 8-K | $2.47 | awaiting T+60 | — | $2.11 (−14.57%) |
Jul 29, 2026 12w ago | 8-K | $2.17 $2.18 | ▲ +0.46% | ▼ −2.00% | $2.11 (−2.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers